Carl June (Brian Ach/Getty Images for TIME 100 Health Summit)
May 6, 2024 03:54 PM EDT
R&D
Cell/Gene Tx

UPenn and Stan­ford analy­sis finds no sec­ondary can­cer cas­es di­rect­ly due to CAR-T

Lei Lei Wu

News Reporter

The Uni­ver­si­ty of Penn­syl­va­nia’s pi­o­neer­ing cell ther­a­py physi­cian Carl June shared new da­ta Mon­day that showed the risk of sec­ondary can­cers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NIH’s fund­ing cut plan pos­es chal­lenges for re­searchers de­spite court halt

Ab­b­Vie pens an­oth­er T cell en­gager deal, this time with Xilio

Bio­gen down­plays ca­pac­i­ty for M&A; Roche’s SMA drug is ap­proved as a tablet

Kaiser Per­ma­nente calls on FDA and Con­gress to firm up ac­cel­er­at­ed ap­proval re­quire­ments

Anap­tys­Bio gets a mid-stage win for PD-1 drug in rheuma­toid arthri­tis

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times